Earnings Summary

Spectrum Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $15.62Mn in the Q1 2023. On a quarterly growth basis, Spectrum Pharmaceuticals, Inc. has generated 54.39% jump in its revenue since last 3-months.

Spectrum Pharmaceuticals, Inc.’s net profit jumped 67.58% since last year same period to $-5.01Mn in the Q1 2023. On a quarterly growth basis, Spectrum Pharmaceuticals, Inc. has generated 44.28% jump in its net profits since last 3-months.

Spectrum Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -32.07% in the Q1 2023. On a quarterly growth basis, Spectrum Pharmaceuticals, Inc. has generated 63.91% jump in its net profit margins since last 3-months.

Spectrum Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a 26.67% jump from last quarter’s estimates.

Spectrum Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.11.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Spectrum Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.38.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Spectrum Pharmaceuticals, Inc.’s return on equity (ROE) stands at -1.65.